Ezetimibe, tablet, 10 mg, Ezetrol®, and Ezetimibe with Simvastatin, tablet, 10 mg – 10 mg, 10 mg – 40 mg and 10 mg – 80 mg, Vytorin® November 2006
Public summary document for Ezetimibe, tablet, 10 mg, Ezetrol®, and Ezetimibe with Simvastatin, tablet, 10 mg – 10 mg, 10 mg – 40 mg and 10 mg – 80 mg, Vytorin®
Page last updated: 02 March 2007
Public Summary Document
Product: Ezetimibe, tablet, 10 mg, Ezetrol, and Ezetimibe with Simvastatin, tablet,
10 mg – 10 mg, 10 mg – 40 mg and 10 mg – 80 mg, Vytorin
Sponsor: Merck Sharp and Dohme (Australia) Pty Ltd
Date of PBAC Consideration: November 2006
1. Purpose of Application
- The submission requested an extension to the current authority required PBS listing of ezetimibe and ezetimibe with simvastatin to include the treatment of patients with hypertension, a family history of coronary heart disease (Part A) or high dose statin intolerance (Part B).
- The submission requested a new strength of ezetimibe with simvastatin (10 mg – 10 mg) to be listed.
2. Background
At the June 2003 meeting, the PBAC recommended an authority required listing for ezetimibe for:
- patients who were eligible to receive lipid lowering medication when statins were unsuitable or contraindicated;
- homozygous sitosterolemia; and
- patients with homozygous familial hypercholesterolaemia in combination with a statin.
The PBAC rejected use when co-administered with statins in patients eligible for subsidised
lipid lowering medication, with coronary heart disease and/or diabetes mellitus, because
of uncertain cost-effectiveness.
At its December 2003 meeting the PBAC recommended listing for patients with coronary
heart disease or diabetes mellitus on the basis of acceptable cost-effectiveness,
noting that although there were residual uncertainties over the modelling, these were
insufficient to cast doubt on the overall acceptability of the conclusions. Also at
this meeting, listing for heterozygous familial hypercholesterolaemia (HeFH) was rejected
because of uncertain clinical benefit and the resulting uncertain cost-effectiveness.
Ezetrol was first listed on 1 August 2004.
The March 2005 PBAC meeting recommended listing of ezetimibe with simvastatin on a
cost-minimisation basis compared to the sum of the corresponding strengths of the
individual components.
The July 2005 meeting amended the previously recommended restriction for ezetimibe
with simvastatin to allow for patients with coronary heart disease or diabetes mellitus
who were inadequately controlled after three months treatment at a daily dose 40 mg
or greater of any statin to commence treatment on Vytorin (ezetimibe with simvastatin),
rather than require patients treated with other statins to take 3 months of concomitant
treatment with ezetimibe and simvastatin prior to commencing the combination product.
At the November 2005 meeting, the PBAC recommended the addition of two indications
to the current listing for ezetimibe and ezetimibe and simvastatin, namely peripheral
vascular disease and heterozygous familial hypercholesterolaemia, on the basis of
acceptable cost-effectiveness in these patient groups. These changes were effective
1 April 2006. The PBAC was unable to agree to the addition of cerebrovascular disease
because the General Statement for Lipid-Lowering Drugs current at the time did not
include this patient group. However, the Committee indicated that it had no objection
to the inclusion of this patient group if and when the recommended changes to the
General Statement occurred.
Vytorin was first listed on 1 February 2006.
On 5 September 2006, an announcement was made that the new General Statement for Lipid
Lowering Drugs as recommended by the PBAC will be implemented on 1 October 2006. The
patient categories may be found at the following website:
http://www.health.gov.au/internet/main/publishing.nsf/content/lipid_eligibilitycriteria.htm
Changes to the lipid levels required for PBS access to EZETROL and VYTORIN and inclusion
of access for patients with symptomatic cerebrovascular disease also took effect from
1 October 2006.
3. Registration Status
Ezetimibe (Ezetrol)
Primary Hypercholesterolaemia: Ezetrol administered alone, or with an HMG-CoA reductase
inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary
(heterozygous familial and non-familial) hypercholesterolaemia.
Homozygous Familial Hypercholesterolaemia (HoFH): Ezetrol, administered with a statin,
is indicated for patients with HoFH. Patients may also receive adjunctive treatments
(e.g. LDL apheresis).
Homozygous Sitosterolaemia (Phytosterolaemia): Ezetrol is indicated for the reduction
of elevated sitosterol and campesterol levels in patients with homozygous familial
sitosterolaemia.
Ezetimibe with Simvastatin (Vytorin)
Vytorin is indicated as adjunctive therapy to diet in patients with primary (heterozygous
familial and non-familial) hypercholesterolaemia or mixed hyperlipidemia where use
of combination product is appropriate: Patients not appropriately controlled with
a statin or ezetimibe alone. Patients already treated with a statin and ezetimibe.
Vytorin is indicated in patients with homozygous familial hypercholesterolaemia (HoFH).
Patients may also receive adjunctive treatments (e.g., LDL apheresis).
4. Listing Requested and PBAC’s View
(Part A - For the indication of family history of coronary heart disease or hypertension)
EZETROL
Authority required
Initial treatment, in conjunction with dietary therapy and exercise, for co-administration
with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels
are inadequately controlled with a statin and who have:
- coronary heart disease; or
- diabetes mellitus; or
- peripheral vascular disease; or
- heterozygous familial hypercholesterolaemia; or
- family history of coronary heart disease; or
- hypertension
Inadequate control with a statin is defined as a cholesterol level in excess of the
initial threshold for PBS-subsidy according to the General Statement for Lipid-Lowering
Drugs after at least 3 months of treatment at a daily dose of 40 mg or greater of
a statin, in conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 1 month old at the time of application.
Continuing treatment for co-administration with HMG CoA reductase
inhibitors (statins) in patients with coronary heart disease or diabetes mellitus
or peripheral vascular disease or heterozygous familial hypercholesterolaemia or family
history of coronary heart disease or hypertension whose cholesterol levels were inadequately
controlled with a statin, where the patient has previously been issued with an authority
prescription for this drug.
EZETROL
(Part B - For the indication of intolerance of high dose statins)
Authority required
Initial treatment, in conjunction with dietary therapy and exercise, for co-administration
with up to 10 mg of a HMG CoA reductase inhibitor (statin) in patients eligible for
PBS subsidised lipid lowering medication (according to the criteria set out in the
General Statement for Lipid Lowering Drugs) who are unable to tolerate 20 mg or greater
of a statin due to a contraindication or experience of a clinically important adverse
event (as defined in the ezetimibe monotherapy listing) and whose cholesterol levels
are inadequately controlled with up to 10 mg of a statin.
Inadequate control with a statin is defined as a cholesterol level in excess of the
initial threshold for PBS-subsidy according to the General Statement for Lipid-Lowering
Drugs after at least 3 months of treatment at a daily dose of up to 10 mg of a statin,
in conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 1 month old at the time of application.
Continuing treatment for co-administration with up to 10 mg of a statin in patients
whose cholesterol levels were inadequately controlled with up to 10 mg of a statin,
where the patient has previously been issued with an authority prescription for this
drug.
EZETIMIBE with SIMVASTATIN
(Part A - For the indication of family history of coronary heart disease or hypertension)
Authority required
Initial treatment, in conjunction with dietary therapy and exercise, in patients whose
cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor
(statin) and who have:
- coronary heart disease; or
- diabetes mellitus; or
- peripheral vascular disease; or
- heterozygous familial hypercholesterolaemia; or
- family history of coronary heart disease; or
- hypertension.
Inadequate control with a statin is defined as a cholesterol level in excess of the
initial threshold for PBS-subsidy according to the General Statement for Lipid-Lowering
Drugs after at least 3 months of treatment at a daily dose of 40 mg or greater of
a statin, in conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 1 month old at the time of application.
Continuing treatment in patients with coronary heart disease or diabetes mellitus
or peripheral vascular disease or heterozygous familial hypercholesterolaemia or family
history of coronary heart disease or hypertension whose cholesterol levels were inadequately
controlled with a statin, where the patient has previously been issued with an authority
prescription for this item or the combination of ezetimibe and 40 mg or greater of
a statin.
NEW STRENGTH – Vytorin 10/10
Authority required
Initial treatment, in conjunction with dietary therapy and exercise, with VYTORIN
10/10 in patients eligible for PBS subsidised lipid lowering medication (according
to the criteria set out in the General Statement for Lipid Lowering Drugs) who are
unable to tolerate 20 mg or greater of a statin due to a contraindication or experience
of a clinically important adverse event (as defined in the ezetimibe monotherapy listing)
and whose cholesterol levels are inadequately controlled with 10 mg of a statin.
Inadequate control with a statin is defined as a cholesterol level in excess of the
initial threshold for PBS-subsidy according to the General Statement for Lipid-Lowering
Drugs after at least 3 months of treatment at a daily dose of 10 mg of a statin, in
conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 1 month old at the time of application.
Continuing treatment with VYTORIN 10/10 in patients whose cholesterol levels were
inadequately controlled with 10 mg of a statin, where the patient has previously been
issued with an authority prescription for this item or the combination of ezetimibe
and 10 mg of a statin.
For PBAC’s view, see Recommendations and Reasons.
5. Clinical Place for the Proposed Therapy
Part A - For the indication of family history of coronary heart disease or hypertension:Family
history of coronary heart disease and hypertension both appear to significantly elevate
the risk of developing coronary heart disease (CHD) in both men and women.
Ezetimibe, a cholesterol absorption inhibitor, has a complementary action to the statins
and provides incremental lipid lowering in patients where adequate lipid lowering
has not been achieved with statins alone, even at maximal recommended doses or tolerated
doses.
Vytorin, a combination of ezetimibe with simvastatin, has similar effectiveness as
the individual components simvastatin and ezetimibe, but with the added convenience
of a single tablet.
Part B - For the indication of intolerance of high dose statins:
Some patients treated with statins are at increased risk of clinically important adverse
events which require the interruption or discontinuation of therapy. Such events are
more likely to occur at higher statin doses. Ezetimibe monotherapy may be an option
for these patients. In other patients a low dose of statin treatment can be tolerated
without apparent clinical symptoms. In these patients the benefits of lipid lowering
with a low dose of statin may outweigh the risk of sub-clinical treatment side-effects.
Ezetimibe may be used as a treatment alternative for patients who are inadequately
controlled on up to 10 mg of a statin and who are unable to tolerate a higher dose
of statin demonstrated by a contraindication or experience of a clinically important
event.
Vytorin 10 mg/10 mg (ezetimibe with simvastatin) may also be used for patients who
are unable to tolerate 20 mg or more of a statin, and are inadequately controlled
on 10 mg of a statin.
6. Comparator
For the indication of family history of coronary heart disease or hypertension (Part
A):
The submission nominated placebo (co-administered with a statin). The PBAC advised
that up-titration with a statin could be considered as an alternative comparator.
For the indication of intolerance of high dose statins (Part B):
The submission nominated placebo. The PBAC advised that ezetimibe monotherapy could
also be a relevant comparator.
See Recommendations and Reasons.
7. Clinical Trials
For the indication of family history of coronary heart disease or hypertension (Part
A):
The submission presented a meta-analysis of six trials where ezetimibe was compared
with placebo as add-on therapy to a statin. In these 6 key studies patients primarily
had established coronary heart disease (CHD) or were CHD risk equivalent. Several
of the studies contained smaller populations of patients with 2 or more CHD risk factors.
Sub-analysis by National Cholesterol Education Program (NCEP) Adult Treatment Panel
(ATP) categories showed little difference in the treatment effect between risk categories.
For the indication of intolerance of high dose statins (Part B):
The submission provided a meta-analysis of the same six trials presented in part A
above. In the trials ezetimibe is compared with placebo as add-on therapy to a statin
in patients who primarily have established CHD or who are CHD risk equivalent. The
submission also included the results from a “before-and-after” study reported by Wierzbicki
et al, 2005, conducted in patients with familial hypercholesterolaemia who had not
achieved NCEP ATP III targets despite maximally tolerated doses of statins, and where
ezetimibe was added as additional therapy to maximally tolerated dose of statins.
The submission provided 65 citations relating to the 19 included randomised controlled
trials which supported the two concurrent requested listings. The key clinical papers
for the published trials are listed below:
Trial |
Description |
Citations |
---|---|---|
Protocol 005 |
Randomised, double-blind placebo-controlled, multicentre trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Goldberg et al.Citations |
Mayo Clin Proc 2004; 79(5):620-629. |
|
Protocol 021 |
Randomised, double-blind, parallel, multicentre trial of 30 weeks comprising of a 6-week, open-label simvastatin 20mg lipid stabilisation period and a 24-week treatment period in type 2 diabetic patients treated with thiazolidinediones. |
|
Gaudiani et al. |
Diabetes, Obesity and Metabolism. 2005; 7(1): 88-97. |
|
Protocol 023 |
Randomised, double-blind, parallel group, multicentre trial of 23 weeks in patients with CHD or CHD risk equivalent as defined by the NCEP Adult Treatment Panel III guidelines. |
|
Feldman et al. |
Am J Cardiol 2004; 93(12):1481-1486. |
|
Protocol 025 |
Randomised, double-blind, parallel group, multicentre trial of 28 weeks in patients with hypercholesterolaemia. |
|
Ballantyne et al. |
Am J Cardiol 2004; 93(12):1487-1494. |
|
Protocol 038 |
Randomised, double-blind, placebo-controlled, multicentre factorial trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Bays et al. |
Clin Ther 2004; 26(11): 1758-1773. |
|
Protocol 051 |
Randomised, double-blind, parallel group, multicentre trial of 6 weeks in patients with primary hypercholesterolaemia. |
|
Ballantyne et al. |
Am Heart J 2005; 149(3): 464-73. |
|
Protocol 058 |
Randomised, double-blind, parallel group, multicentre trial of 6 weeks in patients with primary hypercholesterolaemia. |
|
Abate et al. |
J. Am. Geriatric Society 2006; 54(4, Suppl.):S163-S163 (#D22). |
|
Protocol 679 |
Randomised, double-blind, placebo-controlled, multicentre trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Kerzner et al. |
Am J Cardiol 2003; 91(4): 418-424, 2003. |
|
Protocol 680 |
Randomised, double-blind, placebo-controlled, multicentre trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Davidson et al. |
J Am Coll Cardiol 2002; 40(12): 2125-2134. |
|
Sager et al. |
Am J Cardiol 2003; 92(12): 1414-1418. |
|
Protocol 691 |
Randomised, double-blind, placebo-controlled, multicentre trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Melani et al. |
Eur Heart J 2003; 24(8): 717-728. |
|
Protocol 692 |
Randomised, double-blind, placebo-controlled, multicentre trial of 12 weeks in patients with primary hypercholesterolaemia. |
|
Ballantyne et al. |
Circulation 2003; 107(19): 2409-2415. |
|
Protocol 693 |
Randomised, double-blind, double-dummy, active-control, multicentre trial of 14 weeks in patients with coronary heart disease or multiple cardiovascular risk factors and with primary hypercholesterolaemia not controlled by a starting dose (10mg) of atorvastatin. |
|
Stein et al. |
Am Heart J 2004; 148(3): 447-455. |
|
Protocol 700 |
Randomised, double-blind, dose-titration multicentre trial of 14 weeks in patients with coronary heart disease or multiple cardiovascular risk factors and with primary hypercholesterolaemia not controlled by a starting dose (20mg) of simvastatin. |
|
Dobs et al. |
J Am Coll Cardiol 2003; 41(6, Suppl. A): 227A-227A. |
|
Protocol 801 |
Randomised, double-blind, placebo-controlled, multicentre trial of 6 weeks in patients with hypercholesterolaemia and coronary heart disease. |
|
Brohet et al. |
Curr Med Res Opin 2005; 21(4):571-578. |
|
Protocol 802 |
Randomised, double-blind, placebo-controlled, multicentre trial of 6 weeks in CHD patients with hypercholesterolaemia. |
|
Farnier et al. |
Int J Cardiol 2005; 102(2) 327-332. |
|
Protocol 803 and 804* |
Randomised, double-blind, placebo-controlled, multicentre trial of 6 weeks in patients with hypercholesterolaemia and coronary heart disease. |
|
Cruz-Fernandez et al. |
Int J Clin Pract 2005; 59(6) 619-627. |
|
Protocol 1030 |
Randomised, double-blind, double-dummy, parallel group, multicentre trial of 12 weeks in patients with HoFH. |
|
Gagne C,et al |
Circulation 2002; 105(21):2469-2475. |
|
Protocol 2173 and Protocol 2246 |
Randomised, double-blind, placebo-controlled, multicentre trial of 8 weeks active treatment and 6 weeks reversibility phase in patients with primary hypercholesterolaemia. |
|
Gagne et al. |
Am J Cardiol 2002; 90(10):1084-1091. |
|
EASE Study |
Randomised, double-blind, placebo-controlled, multicentre trial of 6 weeks in patients with hypercholesterolaemia. |
|
Pearson et al. |
Mayo Clin Proc 2005; 80(5) 587-595. |
|
Pearson et al. |
Am J Geriatric Pharmacotherapy 2005; 3(4) 218-228. |
8. Results of Trials
For the indication of family history of coronary heart disease or hypertension (Part
A):
The results of the analyses showed that there were significantly more patients attaining
target LDL-C levels when ezetimibe was added to ongoing statin compared with no addition
to statin therapy.
Overall, differences in mean percent change in LDL-C, HDL-C and Total-C from baseline
to endpoint across the trials also significantly favoured the addition of ezetimibe
to statin monotherapy. The combined estimates for these three lipid parameters were
all statistically significant irrespective of the effects model used.
Generally, there were no differences in the percentage of subjects reporting adverse
effects between patients treated with statin monotherapy and patients treated with
ezetimibe plus a statin.
For the indication of intolerance of high dose statins (Part B):
Results from the supportive study known as Wierzbicki et al, 2005 indicated that the
percentage of patients achieving the lipid targets increased from 2.5% to 4% for NCEP-ATP
III and from 5.5% to 18% for National Service Framework for Coronary Heart Disease
(NSF-CHD).
The difference in the mean percent change from baseline to endpoint for LDL-C, HDL-C
and Total C favoured ezetimibe + statin.
Adverse events in the study reported by Wierzbicki et al, 2005 are similar to those
reported in the trials in Part A.
9. Clinical Claim
For the indication of family history of coronary heart disease or hypertension (Part
A):
The submission claimed that ezetimibe (and ezetimibe + simvastatin) has significant
clinical advantages over placebo and is associated with similar or less toxicity.
For the indication of intolerance of high dose statins (Part B):
The submission claimed that ezetimibe (and ezetimibe + simvastatin 10mg) has significant
clinical advantages over placebo and is associated with similar or less toxicity.
The PBAC considered that this claim was not reasonable. See Recommendations and Reasons.
10. Economic Analysis
For the indication of family history of coronary heart disease or hypertension (Part
A):
A preliminary economic evaluation was presented. The resources included were drug
costs.
Two modelled economic evaluation were presented – one for patients with hypercholesterolaemia
and hypertension and the other for patients with hypercholesterolaemia and family
history of CHD. The resources included were drug costs and costs of CHD and non-CHD
events.
The base case modelled incremental discounted cost/extra life year gained in patients
with hypercholesterolaemia and a family history of CHD over a 70-year time horizon
was estimated to be in the range $15,000- $45,000.
The base case modelled incremental discounted cost/extra life year gained in patients
with hypercholesterolaemia and hypertension over a 70-year time horizon was estimated
to be in the range $15,000- $45,000.
For the indication of intolerance of high dose statins (Part B):
A preliminary economic evaluation was presented. The resources included were drug
costs.
A modelled economic evaluation was presented. The resources included were drug costs
and costs of CHD and non-CHD events.
The base case modelled incremental discounted cost/extra life year gained over a 70-year
time horizon was estimated to be in the range $15,000- $45,000.
11. Estimated PBS Usage and Financial Implications
For the indication of family history of coronary heart disease or hypertension (Part
A):
The likely number of patients/year was estimated to be in the range 10,000 – 50,000
patients with family history of CHD and in the range 10,000 – 50,000 patients with
hypertension in Year 4 of listing.
The financial cost/year to the PBS was estimated to be < $10 million for patients
with family history of CHD and < $10 million for patients with hypertension in Year
4.
For the indication of intolerance of high dose statins (Part B):
The likely number of patients/year was estimated to be in the range 10,000 – 50,000
patients in Year 4 of listing. The financial cost/year to the PBS was estimated to
be in the range $10 – 30 million in Year 4.
The PBAC considered that the estimates of usage for all indications (Part A and Part
B) may result in net costs of > $10 million/year in the first year of listing.
12. Recommendation and Reasons
The PBAC recommended extending the authority required listing of ezetimibe to include
the treatment of patients with hypertension or a family history of coronary heart
disease in patients whose cholesterol levels are inadequately controlled with a statin
according to the current ezetimibe PBS restriction definitions of inadequate control.
Listing was recommended on a cost effectiveness basis against placebo at the price
proposed in the submission.
The PBAC noted that the submission provides evidence that adding ezetimibe to statin
therapy lowers low density lipoprotein (LDL) cholesterol. The restriction proposed
is also not incompatible with currently allowed access to PBS-subsidised treatment
with the statins, and although the absolute risk reduction in some of the patient
groups (eg hypertension, early family history of CHD in 2nd degree relatives) covered
by the new restriction was considered to be less than for those in the CHD risk equivalent
group, this difference is catered for by the differing threshold levels in the General
Statement for Lipid-Lowering Drugs.
The PBAC also recommended extending the authority listing of ezetimibe to include
the treatment of patients who experience a clinically important product-related adverse
event to a statin as defined in the current PBS ezetimibe restriction, but who can
continue to take a statin at a dose of 20 mg per day or less (rather than having to
discontinue the statin completely as currently). This recommendation was made on the
basis of a demonstrated clinical need in a high risk group of patients, where the
cost-effectiveness of treatment is established.
The PBAC shared the concerns of the ESC with respect to appropriate comparators and
indicated that any future applications for extensions to the listing of ezetimibe
either as monotherapy or in combination with simvastatin must be accompanied by a
comparison against a therapeutic strategy where the dose of statin is increased or
a switch to a more potent (on a mg per mg basis) statin is made, eg. simvastatin 20
mg to atorvastatin 20 mg; atorvastatin 20 mg to rosuvastatin 20 mg. These strategies
are increasingly being used in clinical practice and are therefore appropriate additional
comparators to placebo.
The Committee further recommended that the requirement that cholesterol level results
must be no more than 1 month old at the time of authority application be amended to
allow results up to 2 months old to be provided. The PBAC did not consider it clinically
appropriate to allow results up to 4 months old to be provided as requested in the
sponsor’s application. The parallel drawn with the requirement for the thiazolidinediones
by the sponsor was also considered to be inappropriate as the four month interval
allowed for glycosolated haemoglobin (HbA1c) results reflects the fact that HbA1c
levels are slow to change after a therapeutic intervention, and this does not hold
true for cholesterol levels.
Recommendation:
EZETIMIBE, tablet 10 mg
Restriction: Authority required
Initial treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have:
- coronary heart disease or
- diabetes mellitus or
- peripheral vascular disease or
- heterozygous familial hypercholesterolaemia or
- symptomatic cerebrovascular disease or
- family history of coronary heart disease or
- hypertension
Inadequate control with a statin is defined as follows:
- where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise; or
- where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol/L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 2 months old at the time of application.
Continuing treatment for co-administration with HMG CoA reductase inhibitors (statins)
in patients with coronary heart disease or diabetes mellitus or peripheral vascular
disease or heterozygous familial hypercholesterolaemia or symptomatic cerebrovascular
disease or family history of coronary heart disease or hypertension, whose cholesterol
levels were inadequately controlled with a statin, where the patient has previously
been issued with an authority prescription for this drug.
Authority required
Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria
set out in the General Statement for Lipid-Lowering Drugs):
- where treatment with an HMG CoA reductase inhibitor (statin) is contraindicated; or
- where treatment with an HMG CoA reductase inhibitor (statin) must be discontinued or reduced to a dose of 20 mg or less per day, because the patient developed a clinically important product-related adverse event during treatment with a statin.
A clinically important product-related adverse event is defined as follows:
- Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or
- Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or
- Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.
Authority required
Homozygous sitosterolaemia
Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised
lipid-lowering medication (according to the criteria set out in the General Statement
for Lipid-Lowering Drugs), in combination with an HMG CoA reductase inhibitor (statin).
Maximum quantity: 30
Repeats: 5
Recommendation and Reasons:
The PBAC recommended extending the authority required listing of ezetimibe with simvastatin
to include the treatment of patients with hypertension or a family history of coronary
heart disease in patients whose cholesterol levels are inadequately controlled with
a statin according to the current ezetimibe PBS restriction definitions of inadequate
control. Listing was recommended on a cost effectiveness basis against placebo at
the price proposed in the submission.
The PBAC noted that the submission provides evidence that adding ezetimibe to statin
therapy lowers low density lipoprotein (LDL) cholesterol. The restriction proposed
is also not incompatible with currently allowed access to PBS-subsidised treatment
with the statins, and although the absolute risk reduction in some of the patient
groups (eg hypertension, early family history of CHD in 2nd degree relatives) covered
by the new restriction will be much less than for those in the CHD risk equivalent
group, this difference is catered for by the differing threshold levels in the General
Statement for Lipid-Lowering Drugs.
The PBAC indicated that it would not be prepared to consider any future applications
for extensions to the listing of ezetimibe either as monotherapy or in combination
with simvastatin unless these applications were accompanied by a comparison against
a therapeutic strategy where the dose of the statin is increased or a switch is made
to a more potent (on a mg per mg basis) statin, eg. simvastatin 20 mg to atorvastatin
20 mg; atorvastatin 20 mg to rosuvastatin 20 mg. These strategies are increasingly
being used in clinical practice and are therefore an appropriate additional comparator
to placebo for ezetimibe.
The Committee further recommended that the requirement that cholesterol level results
must be no more than 1 month old at the time of authority application be amended to
allow results up to 2 months old to be provided. The PBAC did not consider it clinically
appropriate to allow results up to 4 months old to be provided as requested in the
sponsors application. The parallel drawn with the thiazolidinediones by the sponsor
was also considered to be inappropriate as the four month interval allowed for glycosolated
haemoglobin (HbA1c) results reflects the fact that HbA1c levels are slow to change
after a therapeutic intervention, and this does not hold true for cholesterol levels.
Recommendation
EZETIMIBE with SIMVASTATIN, tablet, 10 mg – 40 mg and 10 mg – 80 mg
Restriction: Authority required
Initial treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have:
- coronary heart disease or
- diabetes mellitus or
- peripheral vascular disease or
- heterozygous familial hypercholesterolaemia or
- cerebrovascular disease which has become symptomatic or
- family history of coronary heart disease or
- hypertension
Inadequate control with a statin is defined as follows:
- where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise; or
- where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol/L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise.
The cholesterol level after 3 months of treatment with a statin and the dose of the
statin must be provided at the time of application. The cholesterol level results
provided must be no more than 2 months old at the time of application.
Continuing treatment in patients with coronary heart disease or diabetes mellitus
or peripheral vascular disease or heterozygous familial hypercholesterolaemia or symptomatic
cerebrovascular disease or family history of coronary heart disease or hypertension,
whose cholesterol levels were inadequately controlled with a statin, where the patient
has previously been issued with an authority prescription for this item or the combination
of ezetimibe and 40 mg or greater of a statin.
Patients with homozygous familial hypercholesterolaemia who are ligible for PBS-subsidised
lipid-lowering medication (according to the criteria set out in the General Statement
for Lipid-Lowering Drugs).
Maximum quantity: 30
Repeats: 5
Recommendation and Reasons:
NEW STRENGTH
EZETIMIBE with SIMVASTATIN, tablet, 10 mg – 10 mg
The PBAC rejected the application to list a new strength of ezetimibe with simvastatin
(10 mg – 10 mg) on the grounds of unclear clinical need, and unnecessary proliferation
of dosage forms. There was also a lack of evidence that patients were at a lower risk
of side effects with this combination than with a 10 mg dose or higher of a more potent
statin. The PBAC noted that a patient was more likely to be switched to a 10 mg dose
of a more potent statin than to require the introduction of ezetimibe and that this
was clinically appropriate.
However, the PBAC recommended extending the authority listing of ezetimibe to include
the treatment of patients who experience a clinically important product-related adverse
event to a statin as defined in the current PBS ezetimibe restriction, but who can
continue to take a statin at a dose of 20 mg per day or less (rather than having to
discontinue the statin completely as currently). This recommendation was made on the
basis of a demonstrated clinical need in a high risk group of patients and addressed
the situation where a patient was unable to tolerate any statin at a dose of higher
than 10 mg.
13. Context for Decision
The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.
14. Sponsor’s Comment
No comment.